Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,469,015

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,469,015 protect, and when does it expire?

Patent 6,469,015 protects DENAVIR and is included in one NDA.

This patent has thirty-four patent family members in twenty-seven countries.

Summary for Patent: 6,469,015
Title: Pharmaceutical formulation
Abstract:An oil-in-water topical pharmaceutical formulation or an aqueous formulation for the treatment of virus infections of the skin or mucosa, comprising at least 30% of propylene glycol and solubilized penciclovir.
Inventor(s): Griffiths; Hazel-Ann (Dorking, GB), Goodall; Alan John (Worthing, GB), Oduro-Yeboah; Joshua (Worthing, GB)
Assignee: Novartis International Pharmaceutical Ltd (Hamilton, BM)
Application Number:08/462,257
Patent Claim Types:
see list of patent claims
Formulation; Use;

Drugs Protected by US Patent 6,469,015

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 RX Yes Yes   Start Trial   Start Trial TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,469,015

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 197   Start Trial
African Regional IP Organization (ARIPO) 9000236   Start Trial
Austria 142880   Start Trial
Australia 643975   Start Trial
Australia 7155891   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.